Literature DB >> 30040734

Heme Oxygenase 1 Induces Tau Oligomer Formation and Synapse Aberrations in Hippocampal Neurons.

Zizhen Si, Xidi Wang, Zhujun Zhang, Jinxin Wang, Jihong Li, Jing Li, Ling Li, Yuanxin Li, Yahui Peng, Chongran Sun, Yang Hui, Xu Gao.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by behavioral changes and cognitive decline. Recent evidence suggests that it is the soluble forms of tau oligomers (Tau-O) and Aβ oligomers (oAβ) rather than the well-studied insoluble protein aggregates that possess the neurotoxicity, infectivity, and amplification underlying disease progression. Heme oxygenase 1 (HO-1), an inducible enzyme upregulated in the cortex and hippocampus of AD brains, was reported to damage neural structures and disrupt brain function, suggesting possible contributions to Tau-O-mediated neurodegeneration. In this study, we focused on the effects of HO-1 on Tau-O formation. In hippocampus of HO-1-overexpressing transgenic mice and neural 2a (N2a) cells, Tau-O was co-localized with HO-1 as visualized by immunofluorescence staining. Furthermore, primary cultured hippocampal neurons from HO-1 transgenic mice showed elevated Tau-O and concomitant reductions in spine density and length as well as dendritic length, diameter, and arborization. Blocking Tau-O formation by isoprenaline reversed these HO-1-induced morphological changes. These results indicated that HO-1 contributes to Tau-O formation and ensuing synaptic damage. Thus, HO-1 is a promising target for AD drug development.

Entities:  

Keywords:  Alzheimer’s disease; dendritic spine; heme oxygenase 1; synaptic plasticity; tau oligomer

Mesh:

Substances:

Year:  2018        PMID: 30040734     DOI: 10.3233/JAD-180451

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  4 in total

1.  Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease.

Authors:  Christian Griñán-Ferré; Sandra Codony; Eugènia Pujol; Jun Yang; Rosana Leiva; Carmen Escolano; Dolors Puigoriol-Illamola; Júlia Companys-Alemany; Rubén Corpas; Coral Sanfeliu; Belen Pérez; M Isabel Loza; José Brea; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez; Mercè Pallàs; Carles Galdeano
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

2.  Aging and Progression of Beta-Amyloid Pathology in Alzheimer's Disease Correlates with Microglial Heme-Oxygenase-1 Overexpression.

Authors:  Cristina Fernández-Mendívil; Miguel A Arreola; Lindsay A Hohsfield; Kim N Green; Manuela G Lopez
Journal:  Antioxidants (Basel)       Date:  2020-07-21

3.  The application of weighted gene co-expression network analysis in identifying key modules and hub genes associated with disease status in Alzheimer's disease.

Authors:  Yan Sun; Jinghan Lin; Liming Zhang
Journal:  Ann Transl Med       Date:  2019-12

4.  MicroRNA-320a inhibits invasion and metastasis in osteosarcoma by targeting cytoplasmic polyadenylation element-binding protein 1.

Authors:  Yanlong Wang; Jiyu Yang; Pangtao Chen; Yu Song; Weizheng An; Haoran Zhang; Butegeleqi Butegeleqi; Jinglong Yan
Journal:  Cancer Med       Date:  2020-02-17       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.